Robeco Institutional Asset Management B.V. Purchases 26,723 Shares of Hologic, Inc. (NASDAQ:HOLX)

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 11.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 266,700 shares of the medical equipment provider's stock after purchasing an additional 26,723 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.11% of Hologic worth $21,725,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in HOLX. Innealta Capital LLC acquired a new stake in Hologic during the 2nd quarter worth $25,000. Wolff Wiese Magana LLC purchased a new stake in Hologic during the 3rd quarter valued at about $25,000. iA Global Asset Management Inc. acquired a new stake in Hologic in the 1st quarter valued at about $37,000. Sunbelt Securities Inc. purchased a new position in Hologic during the second quarter worth approximately $37,000. Finally, Cromwell Holdings LLC raised its stake in Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider's stock worth $44,000 after purchasing an additional 416 shares during the period. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Stock Down 1.2 %

NASDAQ:HOLX traded down $0.98 on Thursday, reaching $79.51. The stock had a trading volume of 670,444 shares, compared to its average volume of 1,591,001. The company has a 50-day moving average of $81.05 and a 200 day moving average of $78.12. The stock has a market cap of $18.47 billion, a P/E ratio of 24.17, a price-to-earnings-growth ratio of 3.03 and a beta of 0.98. Hologic, Inc. has a 12-month low of $66.93 and a 12-month high of $84.67. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.01. The firm had revenue of $987.90 million during the quarter, compared to analyst estimates of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 20.11%. Hologic's revenue was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.89 EPS. On average, research analysts predict that Hologic, Inc. will post 4.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on HOLX. Evercore ISI lifted their target price on Hologic from $78.00 to $82.00 and gave the company an "in-line" rating in a report on Tuesday, October 1st. Raymond James boosted their price objective on shares of Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a research report on Tuesday. JPMorgan Chase & Co. lifted their price target on shares of Hologic from $92.00 to $94.00 and gave the stock an "overweight" rating in a research note on Tuesday. Stephens restated an "overweight" rating and issued a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Finally, StockNews.com downgraded Hologic from a "buy" rating to a "hold" rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $89.25.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.